epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Dupixent
    dupilumab
  • remove Ebglyss (lebrikizumab-lbkz)
    lebrikizumab
  • remove Rinvoq
    upadacitinib
  • remove Vtama
    tapinarof topical

multicheck MultiCheck Results - 3 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Dupixent (dupilumab) + Rinvoq (upadacitinib)

Avoid/Use Alternative


dupilumab + upadacitinib

avoid combo: combo may incr. risk of serious infection (additive effects)

Caution Advised

Smiley face Smiley face Dupixent (dupilumab) + Ebglyss (lebrikizumab-lbkz) (lebrikizumab)

Caution Advised


dupilumab + lebrikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Ebglyss (lebrikizumab-lbkz) (lebrikizumab) + Rinvoq (upadacitinib)

Caution Advised


lebrikizumab + upadacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information